CLINICAL SIGNIFICANCE OF PROGRAMMED DEATH-1 LIGAND-1 EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: A 5-YEAR-FOLLOW-UP STUDY

被引：0
|
作者：
Chen, Y-B [1 ]
Mu, C-Y [1 ]
Huang, J-A [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Dept Resp Med, Suzhou, Peoples R China
来源：
RESPIROLOGY | 2011年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：163 / 163
页数：1
相关论文
共 50 条
  • [1] Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study
    Chen, Yan-bin
    Mu, Chuan-Yong
    Huang, Jian-An
    TUMORI, 2012, 98 (06) : 751 - 755
  • [2] Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC)
    Velcheti, Vamsidhar
    Schalper, Kurt
    Carvajal, Daniel
    Chen, Lieping
    Sznol, Mario
    Gettinger, Scott N.
    Herbst, Roy S.
    Rimm, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Programmed death ligand-1 expression in non-small cell lung cancer
    Velcheti, Vamsidhar
    Schalper, Kurt A.
    Carvajal, Daniel E.
    Anagnostou, Valsamo K.
    Syrigos, Konstantinos N.
    Sznol, Mario
    Herbst, Roy S.
    Gettinger, Scott N.
    Chen, Lieping
    Rimm, David L.
    LABORATORY INVESTIGATION, 2014, 94 (01) : 107 - 116
  • [4] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
    Ohigashi, Y
    Sho, M
    Yamada, Y
    Tsurui, Y
    Hamada, K
    Ikeda, N
    Mizuno, T
    Yoriki, R
    Kashizuka, H
    Yane, K
    Tsushima, F
    Otsuki, N
    Yagita, H
    Azuma, M
    Nakajima, Y
    CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2947 - 2953
  • [5] Clinical Significance of Endothelial Programmed Cell Death Ligand 1 Expression in Patients with Non-Small Cell Lung Cancer
    Saito, T.
    Ishida, M.
    Maru, N.
    Utsumi, T.
    Matsui, H.
    Taniguchi, Y.
    Hino, H.
    Murakawa, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S559 - S559
  • [6] Clinical Significance of Programmed Death-1 Ligand-2 in Esophageal Cancer: Comparison with Programmed Death-1 Ligand-1
    Okadome, Kazuo
    Baba, Yoshifumi
    Yagi, Taisuke
    Kiyozumi, Yuki
    Eto, Kojiro
    Hiyoshi, Yukiharu
    Ishimoto, Takatsugu
    Nagai, Yohei
    Iwagami, Shiro
    Miyamoto, Yuji
    Yoshida, Naoya
    Baba, Hideo
    CANCER SCIENCE, 2018, 109 : 414 - 414
  • [7] Clinical significance and therapeutic potential of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer
    Grimm, M.
    Gasser, M.
    Koenigshausen, M.
    Stein, C.
    Lutz, J.
    Krol, S.
    Thiede, A.
    Heemann, U.
    Waaga-Gasser, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Oncogene mutations in non-small cell lung cancer patients in Iran: a study of their association with programmed death ligand-1 expression
    Abrehdari-Tafreshi, Zahra
    Pirestani, Majid
    Mosaferi, Zahra
    Rakhshani, Nasser
    Arefian, Ehsan
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2025, 19 (01)
  • [9] Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer
    Zhang, Ying
    Zhu, Weipei
    Zhang, Xueguang
    Qu, Qiuxia
    Zhang, Liyuan
    ONCOLOGY LETTERS, 2017, 14 (06) : 7225 - 7231
  • [10] Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer
    Fukuda, Minoru
    Yamaguchi, Hiroyuki
    Mukae, Hiroshi
    Ashizawa, Kazuto
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4082 - S4084
12345